Related Experiment Video
Updated: Jul 7, 2026
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Adrenergic modulation of dendritic cell cancer vaccine in a mouse model: role of dendritic cell maturation
Francesca Botta1, Georges J M Maestroni
1Center for Experimental Pathology, Istituto Cantonale di Patologia, Locarno, Switzerland.
Abstract:
The aim of the present study was to evaluate the role of beta2-adrenergic receptors (beta2-ARs) in the outcome of a dendritic cell (DC)-based cancer vaccine in the murine E.G7-ovalbumin (OVA) model. We found that unlike the beta2-AR expressed on antigen loaded DCs, beta2-ARs expressed in the site of DCs inoculation may influence the efficacy of the antitumor response. Intradermal injection of Staphylococcus aureus peptidoglycan along with the beta2-AR-specific antagonist ICI 118,551 increased the local innate cytokine response in tumor-bearing mice. When the adoptive transfer of immature DCs loaded with OVA followed this skin preconditioning, the antitumor response was increased and tumor growth was significantly reduced. Surprisingly, when OVA-loaded mature DCs were used, the effect of the skin preconditioning was the opposite and tumor growth was similar to that observed in control, nonimmunized mice. The extent of the antitumor response on transfer of immature or mature DCs was mediated by a different migration in the draining lymph nodes and by a distinct recruitment of endogenous DCs that resulted in a modulation of the OVA-specific cytotoxic T lymphocyte response. The unexpected tolerogenic effect exerted by mature DCs on skin preconditioning was apparently mediated by the expression of a distinctive pattern of cytokines and of the suppressive enzyme indoleamine 2, 3-dioxygenase in draining lymph nodes. In conclusion, we found that beta2-ARs inhibition along with toll-like receptor2 activation at the site of cancer vaccination may either enhance the resulting antitumor response or be tolerogenic in dependence of the maturation state of the transferred DCs.
Insights
Beta2-adrenergic receptor (beta2-AR) inhibition at the vaccination site enhances anti-tumor response with immature dendritic cells (DCs) but induces tolerance with mature DCs. This impacts cytotoxic T lymphocyte response and tumor growth.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- Beta2-adrenergic receptors (beta2-ARs) play a role in immune responses.
- Dendritic cells (DCs) are crucial for initiating anti-tumor immunity.
- Modulating the tumor microenvironment can impact vaccine efficacy.
Purpose of the Study:
- To investigate the role of beta2-ARs in a dendritic cell (DC)-based cancer vaccine model.
- To determine how beta2-AR blockade affects anti-tumor responses in combination with DC vaccination.
- To explore the influence of DC maturation state on the outcome of beta2-AR inhibition.
Main Methods:
- Utilized the E.G7-ovalbumin (OVA) murine model for cancer vaccination.
- Administered Staphylococcus aureus peptidoglycan and a beta2-AR antagonist (ICI 118,551) for skin preconditioning.
- Adoptively transferred OVA-loaded immature or mature DCs.
- Assessed anti-tumor response, tumor growth, immune cell migration, and cytokine profiles.
Main Results:
- Beta2-AR blockade combined with skin preconditioning enhanced anti-tumor responses and reduced tumor growth when immature DCs were used.
- The same preconditioning strategy led to tolerogenic effects and similar tumor growth as controls when mature DCs were employed.
- Differential migration of DCs to lymph nodes and distinct cytotoxic T lymphocyte responses were observed based on DC maturation state.
- Mature DCs induced tolerance via specific cytokine patterns and indoleamine 2,3-dioxygenase expression.
Conclusions:
- Beta2-AR inhibition at the vaccination site, combined with toll-like receptor 2 activation, can either enhance or suppress anti-tumor responses.
- The outcome is dependent on the maturation state of the transferred dendritic cells (DCs).
- Targeting beta2-ARs offers a potential strategy for cancer immunotherapy, but requires careful consideration of DC status.
